This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Earnings Season Could Be Great for Merck (MRK)
by Zacks Equity Research
Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan
by Zacks Equity Research
Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.
Top Research Reports for Novo Nordisk, AMD & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Will Merck (MRK) Beat Expectations This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.
The Zacks Analyst Blog Highlights Amgen, Chevron, Coca-Cola, Visa and Merck
by Zacks Equity Research
Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.
5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week
by Nalak Das
Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $86.46, marking a +0.78% move from the previous day.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
by Zacks Equity Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.
Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev
by Zacks Equity Research
The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
Anthem (ANTM) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Anthem's (ANTM) first-quarter results are likely to benefit from the growing premiums and an uptick in Medicare and Medicaid membership, partly offset by higher expenses.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Merck (MRK) Stock Moves -1.2%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $86.63, moving -1.2% from the previous trading session.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
by Zacks Equity Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
by Kinjel Shah
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
The Zacks Analyst Blog Highlights Merck, CVS Health, American Tower, QUALCOMM and Analog Devices
by Zacks Equity Research
Merck, CVS Health, American Tower, QUALCOMM and Analog Devices are part of top Analyst article.
Top Analyst Reports for Merck, CVS Health & American Tower
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co. Inc. (MRK), CVS Health Corporation (CVS), and American Tower Corporation (AMT).